Combining the previous related reports that LAT1 over-expression predicts short survival of glioma patients [17], blocking the activity of LAT1 with a system L selective inhibitor can markedly inhibit the growth of glioma cells and induce considerable apoptosis of glioma cells [18], as well as the expression distribution features of LAT1/4F2hc whereby LAT1 is only definitely expressed in few human normal tissues or organs including the placenta, testis and bone marrow, whereas 4F2hc is ubiquitously expressed in various human normal tissues or organs [5]. The gene discussed is SLC3A2; the disease is glioma.